These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 30422005)

  • 1. Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer.
    Batra A; Winquist E
    Expert Opin Emerg Drugs; 2018 Dec; 23(4):271-282. PubMed ID: 30422005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer.
    Seisen T; Rouprêt M; Gomez F; Malouf GG; Shariat SF; Peyronnet B; Spano JP; Cancel-Tassin G; Cussenot O
    Cancer Treat Rev; 2016 Jul; 48():25-33. PubMed ID: 27327958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
    Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.
    Stice JP; Wardell SE; Norris JD; Yllanes AP; Alley HM; Haney VO; White HS; Safi R; Winter PS; Cocce KJ; Kishton RJ; Lawrence SA; Strum JC; McDonnell DP
    Mol Cancer Res; 2017 Jun; 15(6):660-669. PubMed ID: 28209757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in the mechanism and drug development of castration-resistant prostate cancer.
    Zuo M; Xu X; Li T; Ge R; Li Z
    Future Med Chem; 2016 May; 8(7):765-88. PubMed ID: 27149562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
    Fujimoto N
    J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abiraterone acetate for the treatment of prostate cancer.
    Ryan CJ; Cheng ML
    Expert Opin Pharmacother; 2013 Jan; 14(1):91-6. PubMed ID: 23199349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer.
    Han CS; Patel R; Kim IY
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):967-75. PubMed ID: 25936418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing therapies in metastatic castration-resistant prostate cancer.
    Baciarello G; Gizzi M; Fizazi K
    Expert Opin Pharmacother; 2018 Nov; 19(16):1797-1804. PubMed ID: 30311804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].
    Basset V; Flamand V; Crouzet S; Ploussard G
    Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.
    Recine F; Ceresoli GL; Baciarello G; Cerbone L; Calabrò F
    Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):400-10. PubMed ID: 26337241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
    Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M
    Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequencing of agents for castration-resistant prostate cancer.
    Hurwitz M; Petrylak DP
    Oncology (Williston Park); 2013 Nov; 27(11):1144-9, 1154-8. PubMed ID: 24575543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging agents for the therapy of advanced prostate cancer.
    Hathaway AR; Baker MK; Sonpavde G
    Future Oncol; 2015; 11(20):2775-87. PubMed ID: 26367474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D; De Bono JS
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
    Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.